These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32763065)

  • 1. Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma.
    Behrens C; Rocha P; Parra ER; Feng L; Rodriguez-Canales J; Solis LM; Mino B; Zhang J; Gibbons DL; Sepesi B; Rice D; Heymach JV; Moran C; Creighton CJ; Lee JJ; Kadara H; Wistuba II
    Clin Lung Cancer; 2021 May; 22(3):e415-e424. PubMed ID: 32763065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
    Kadara H; Choi M; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Yoo Y; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Wistuba II; Herbst RS
    Ann Oncol; 2017 Jan; 28(1):75-82. PubMed ID: 27687306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
    Ricciuti B; Arbour KC; Lin JJ; Vajdi A; Vokes N; Hong L; Zhang J; Tolstorukov MY; Li YY; Spurr LF; Cherniack AD; Recondo G; Lamberti G; Wang X; Venkatraman D; Alessi JV; Vaz VR; Rizvi H; Egger J; Plodkowski AJ; Khosrowjerdi S; Digumarthy S; Park H; Vaz N; Nishino M; Sholl LM; Barbie D; Altan M; Heymach JV; Skoulidis F; Gainor JF; Hellmann MD; Awad MM
    J Thorac Oncol; 2022 Mar; 17(3):399-410. PubMed ID: 34740862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of tumor-associated immune cells in laryngeal squamous cell carcinoma.
    Zhou L; Li Y; Gao W; Huangfu H; Wen S; Zhang C; Zhao Q; Dong Z; Qu C; Li G; Wu L; Wang B
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1761-1772. PubMed ID: 31115672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas.
    Goldschmid H; Kluck K; Ball M; Kirchner M; Allgäuer M; Winter H; Herth F; Heußel CP; Pullamsetti SS; Savai R; Yong TTK; Schirmacher P; Peters S; Thomas M; Christopoulos P; Budczies J; Stenzinger A; Kazdal D
    Lung Cancer; 2023 Jun; 180():107212. PubMed ID: 37141769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
    Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
    J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Less immune cell infiltration and worse prognosis after immunotherapy for patients with lung adenocarcinoma who harbored STK11 mutation.
    Wang H; Guo J; Shang X; Wang Z
    Int Immunopharmacol; 2020 Jul; 84():106574. PubMed ID: 32413741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung adenocarcinoma patients with KEAP1 mutation harboring low immune cell infiltration and low activity of immune environment.
    Cheng W; Xu B; Zhang H; Fang S
    Thorac Cancer; 2021 Sep; 12(18):2458-2467. PubMed ID: 34328274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
    Front Immunol; 2021; 12():677169. PubMed ID: 34354701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma.
    Rocha P; Salazar R; Zhang J; Ledesma D; Solorzano JL; Mino B; Villalobos P; Dejima H; Douse DY; Diao L; Mitchell KG; Le X; Zhang J; Weissferdt A; Parra-Cuentas E; Cascone T; Rice DC; Sepesi B; Kalhor N; Moran C; Vaporciyan A; Heymach J; Gibbons DL; Lee JJ; Kadara H; Wistuba I; Behrens C; Solis LM
    Cancer Immunol Immunother; 2021 Jul; 70(7):1965-1976. PubMed ID: 33416944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.
    Zhang W; Li Y; Lyu J; Shi F; Kong Y; Sheng C; Wang S; Wang Q
    Cancer Sci; 2022 Mar; 113(3):891-903. PubMed ID: 34967077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma.
    Park C; Na KJ; Choi H; Ock CY; Ha S; Kim M; Park S; Keam B; Kim TM; Paeng JC; Park IK; Kang CH; Kim DW; Cheon GJ; Kang KW; Kim YT; Heo DS
    Theranostics; 2020; 10(23):10838-10848. PubMed ID: 32929383
    [No Abstract]   [Full Text] [Related]  

  • 14. The predictive value of E2F7 in immunotherapy efficacy for lung adenocarcinoma: An observational study.
    Cui H; Li H; Liu J; Zhao P; Liu Y; Zhong R; Li R; Cheng Y
    Medicine (Baltimore); 2024 Jun; 103(25):e38574. PubMed ID: 38905387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy.
    Liao Y; He D; Wen F
    Immunogenetics; 2021 Oct; 73(5):369-380. PubMed ID: 34302518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redox
    Wei XW; Lu C; Zhang YC; Fan X; Xu CR; Chen ZH; Wang F; Yang XR; Deng JY; Yang MY; Gou Q; Mei SQ; Luo WC; Zhong RW; Zhong WZ; Yang JJ; Zhang XC; Tu HY; Wu YL; Zhou Q
    Oncoimmunology; 2024; 13(1):2340154. PubMed ID: 38601319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
    Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma.
    Chen Z; Chen J; Ren D; Zhang J; Yang Y; Zhang H; Mao B; Ma H
    Aging (Albany NY); 2020 Dec; 13(1):598-618. PubMed ID: 33288738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex-biased molecular differences in lung adenocarcinoma are ethnic and smoking specific.
    Li X; Wei S; Deng L; Tao H; Liu M; Zhao Z; Du X; Li Y; Hou J
    BMC Pulm Med; 2023 Mar; 23(1):99. PubMed ID: 36964522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.